You can buy Bortenat at the lowest price in the online pharmacy Nextgen.ooo . Bortezomib is a proteasome inhibitor used to treat multiple myeloma. Bortezomib is a dipeptide derivative of boronic acid and a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: the main mechanism of action of bortezomib is believed to be reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells. However, several mechanisms may be involved in the anticancer activity of bortezomib.
 
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor to be approved by the FDA under the trade name VELCADE.
 
Bortezomib targets the ubiquitin-proteasome pathway, an important molecular pathway that regulates intracellular protein concentrations and promotes protein degradation. The ubiquitin-proteasome pathway is often disrupted in disease states, leading to aberrant signaling and the formation of malignant cells. In one study, patient-derived chronic lymphocytic leukemia (CLL) cells contained 3-fold higher levels of chymotrypsin-like proteasome activity than normal lymphocytes. By reversibly inhibiting the proteasome, bortezomib prevents proteasome-mediated proteolysis. Bortezomib is cytotoxic to a variety of cancer cell types in vitro and delays tumor growth in vivo in non-clinical tumor models. Bortezomib inhibits proteasome activity in a dose-dependent manner. In one pharmacodynamic study, greater than 75% proteasome inhibition was observed in whole blood samples within one hour of bortezomib administration.